Zhongguo Linchuang Yixue (Oct 2024)
Expert consensus on clinical application of 177Lu-prostate specific membrane antigen radio-ligand therapy in prostate cancer
- Guobing LIU,
- Weihai ZHUO,
- Yushen GU,
- Zhi YANG,
- Yue CHEN,
- Wei FAN,
- Jianming GUO,
- Jian TAN,
- Xiaohua ZHU,
- Li HUO,
- Xiaoli LAN,
- Biao LI,
- Weibing MIAO,
- Shaoli SONG,
- Hao XU,
- Rong TIAN,
- Quanyong LUO,
- Feng WANG,
- Xuemei WANG,
- Aimin YANG,
- Dong DAI,
- Zhiyong DENG,
- Jinhua ZHAO,
- Xiaoliang CHEN,
- Yan FAN,
- Zairong GAO,
- Xingmin HAN,
- Ningyi JIANG,
- Anren KUANG,
- Yansong LIN,
- Fugeng LIU,
- Cen LOU,
- Xinhui SU,
- Lijun TANG,
- Hui WANG,
- Xinlu WANG,
- Fuzhou YANG,
- Hui YANG,
- Xinming ZHAO,
- Bo YANG,
- Xiaodong HUANG,
- Jiliang CHEN,
- Sijin LI,
- Jing WANG,
- Yaming LI,
- Hongcheng SHI
Affiliations
- Guobing LIU
- Zhongshan Hospital, Fudan University
- Weihai ZHUO
- Institute of Radiation Medicine, Fudan University
- Yushen GU
- Zhongshan Hospital, Fudan University
- Zhi YANG
- Beijing Cancer Hospital
- Yue CHEN
- The Affiliated Hospital of Southwest Medical University
- Wei FAN
- Sun Yat-sen University Cancer Center
- Jianming GUO
- Zhongshan Hospital, Fudan University
- Jian TAN
- Tianjin Medical University General Hospital
- Xiaohua ZHU
- Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology
- Li HUO
- Peking Union Medical College Hospital
- Xiaoli LAN
- Union Hospital, Tongji Medical College of Huazhong University of Science and Technology
- Biao LI
- Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
- Weibing MIAO
- The First Affiliated Hospital of Fujian Medical University
- Shaoli SONG
- Fudan University Shanghai Cancer Center
- Hao XU
- The First Affiliated Hospital of Jinan University
- Rong TIAN
- West China Hospital, Sichuan University
- Quanyong LUO
- Shanghai Sixth People’s Hospital, Shanghai Jiao Tong University School of Medicine
- Feng WANG
- Nanjing First Hospital
- Xuemei WANG
- The First Affiliated Hospital of University of Science and Technology of China
- Aimin YANG
- The First Affiliated Hospital of Xi’an Jiaotong University
- Dong DAI
- Tianjin Cancer Hospital Airport Hospital
- Zhiyong DENG
- Yunnan Cancer Hospital
- Jinhua ZHAO
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Xiaoliang CHEN
- Chongqing University Cancer Hospital
- Yan FAN
- Peking University First Hospital
- Zairong GAO
- Union Hospital, Tongji Medical College of Huazhong University of Science and Technology
- Xingmin HAN
- The First Affiliated Hospital of Zhengzhou University
- Ningyi JIANG
- The Seventh Affiliated Hospital, Sun Yat-sen University
- Anren KUANG
- West China Hospital, Sichuan University
- Yansong LIN
- Peking Union Medical College Hospital
- Fugeng LIU
- Beijing Hospital
- Cen LOU
- Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
- Xinhui SU
- The First Affiliated Hospital, Zhejiang University School of Medicine
- Lijun TANG
- Jiangsu Province Hospital
- Hui WANG
- Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
- Xinlu WANG
- The First Affiliated Hospital of Guangzhou Medical University
- Fuzhou YANG
- Yaan People’s Hospital
- Hui YANG
- Henan Cancer Hospital
- Xinming ZHAO
- The Fourth Hospital of Hebei Medical University
- Bo YANG
- Anning First People’s Hospital, Kunming University of Science and Technology
- Xiaodong HUANG
- Shanghai Guohe Science & Technology Development Co., Ltd.
- Jiliang CHEN
- Division of Radiation Safety Regulation, Shanghai Municipal Bureau of Ecology and Environment
- Sijin LI
- First Hospital of Shanxi Medical University
- Jing WANG
- Xijing Hospital, Air Force Military University
- Yaming LI
- The First Hospital of China Medical University
- Hongcheng SHI
- Zhongshan Hospital, Fudan University
- DOI
- https://doi.org/10.12025/j.issn.1008-6358.2024.20240893
- Journal volume & issue
-
Vol. 31,
no. 5
pp. 844 – 850
Abstract
177Lu- prostate specific membrane antigen (PSMA) radio-ligand therapy has been approved abroad for advanced prostate cancer and has been in several clinical trials in China. Based on domestic clinical practice and experimental data and referred to international experience and viewpoints, the expert group forms a consensus on the clinical application of 177Lu-PSMA radio-ligand therapy in prostate cancer to guide clinical practice.
Keywords
